Agile Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative women's healthcare products. The company is based in Princeton, New Jersey and was founded in 1997. Agile Therapeutics is committed to improving the lives of women by providing safe and effective healthcare solutions.
Agile Therapeutics' main product is Twirla, a contraceptive patch that delivers a combination of hormones through the skin. Twirla is designed to be easy to use and provide women with a convenient and effective method of birth control. The patch is worn for a week at a time and is replaced with a new patch each week.
Twirla has been approved by the U.S. Food and Drug Administration (FDA) and is available by prescription in the United States. The patch has been shown to be highly effective in preventing pregnancy, with a failure rate of less than 1% when used correctly. Twirla is also well-tolerated by users, with few side effects reported.
Agile Therapeutics is also working on the development of other women's healthcare products, including a product for the treatment of heavy menstrual bleeding. The company's pipeline of products is focused on addressing unmet needs in women's healthcare and improving patient outcomes.
Agile Therapeutics has a strong financial position, with a focus on operational efficiency and cost control. The company's revenue has been steadily increasing in recent years, driven by the commercialization of Twirla. Agile Therapeutics' diversified pipeline and commitment to research and development also provide potential for future growth.
Agile Therapeutics Inc. is a promising biopharmaceutical company with a strong focus on women's healthcare. The commercialization of Twirla and the development of other innovative products position the company for potential growth in the future. As with any investment, it is important to do your due diligence and carefully consider your own investment objectives and risk tolerance before making a decision.